ArticleIn vitro cellular & developmental biology. Animal2026
Bletilla striata polysaccharide inhibits osteoclast differentiation by suppressing macrophage glycolysis and MMP9 expression.
Article in In vitro cellular & developmental biology. Animal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Utilizing single-cell RNA sequencing and network pharmacology, this study explored the mechanism by which Bletilla striata polysaccharide (BSP) mitigates peri-implantitis-associated osteolysis. Integrated analyses revealed a significant expansion of pro-inflammatory macrophages and osteoclasts in diseased tissues, with differentially expressed genes enriched in glycolytic pathways. Mechanistic exploration indicated that BSP suppresses osteoclastogenesis primarily by targeting matrix metalloproteinase-9 (MMP9), thereby inhibiting proteolytic activity and cytoskeletal remodeling. Preliminary rescue experiments supported this notion, showing that while BSP effectively downregulated LPS-induced MMP9 upregulation and suppressed macrophage glycolytic metabolism, forced overexpression of MMP9 partially restored MMP9 levels and reversed the inhibitory effect of BSP on osteoclast formation. These findings suggest a potential "metabolism-protease" interplay, where BSP concurrently modulates immune metabolism and protease activity to alleviate inflammatory bone loss, providing a foundational basis for developing plant-derived polysaccharide therapeutics.
Indexed as
Identifiers
42562998What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.